Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sucampo Pharmaceuticals Inc Announces Positive Top-Line Results in Phase 1a Trials of Cobiprostone and SPI-3608


Wednesday, 7 Aug 2013 08:02pm EDT 

Sucampo Pharmaceuticals Inc announced the positive top-line results of two recently completed clinical trials, a Phase 1a trial of cobiprostone and a Phase 1a trial of SPI-3608. The studies tested the tolerability and pharmacokinetic profiles versus placebo of the two compounds, both of which were demonstrated to be generally well-tolerated in the tested populations. 

Company Quote

6.6
-0.03 -0.45%
4:00pm EDT